Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
Stocks · News reference
Cerenome Enters Into Financing Agreement With 3i LP For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Capital will support continued CNSide® commercial scale-up and developmentInitial tranche of funding provided at closing with future tranches linked to milestonesForecasted cash runway now into 2028HOUSTON, Sept. 10,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — CERENOME, INC. (CNSY)
Filed: 2026-09-10 AccNo: 0001193125-26-387267 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Cerenome Enters Financing Agreement With 3i Fund For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary